Skip to main content
SUTRO BIOPHARMA, INC. logo

SUTRO BIOPHARMA, INC. — Investor Relations & Filings

Ticker · STRO ISIN · US8693671021 LEI · 5493005U6P15VD25P851 US Manufacturing
Open in API
Filings indexed 585 across all filing types
Latest filing 2024-04-26 Proxy Solicitation & In…
Country US United States of America
Listing US STRO

About SUTRO BIOPHARMA, INC.

https://www.sutrobio.com/

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of precisely designed cancer therapeutics. The company leverages its proprietary, integrated cell-free protein synthesis platform to create novel antibody-drug conjugates (ADCs). This technology enables the development of next-generation ADCs, including those with single and dual payloads, which are designed to offer improved therapeutic profiles for patients with cancer. Sutro is advancing its own pipeline of clinical-stage product candidates to address areas of significant unmet medical need.

Recent filings

Filing Released Lang Actions
DEF 14A
Proxy Solicitation & Information Statement
2024-04-26 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically titled as a 'Definitive Additional Materials' related to the proxy statement for Sutro Biopharma, Inc.'s 2024 Annual Meeting. It includes voting items such as election of directors, ratification of auditors, executive compensation advisory vote, and amendment of an employee stock purchase plan. The content is focused on soliciting shareholder votes and providing information for the upcoming meeting, which aligns with the definition of Proxy Solicitation & Information Statement (PSI). The document length is 3400 characters, which is consistent with a proxy statement or related materials rather than a full annual report or other filings. Therefore, the correct classification is PSI with high confidence.
2024-04-26 English
Director's Dealing 2024
Director's Dealing
2024-04-12 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-05 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the company's entry into a material definitive agreement for an underwriting agreement to issue and sell shares, including details about the offering size, price, and use of proceeds. This is a clear update on a capital raising event. There are no financial statements or detailed financial results presented, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a proxy, earnings release, or management discussion. The primary focus is on the financing transaction. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just an announcement of a report publication or certification, so it is not RPA or RNS.
2024-04-02 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a common stock offering by Sutro Biopharma, Inc. It details the terms of the stock offering, underwriting discounts, use of proceeds, risk factors, and recent developments including a license agreement and investment agreement. The document is a formal offering document related to capital raising activities, not a financial report, earnings release, or management discussion. It is not an announcement of a report publication but the actual offering document. Therefore, it fits the category of Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2024-04-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.